Percutaneous, image-guided tumor ablation has evolved as a genuine alternative for the treatment of unresectable hepatocellular carcinoma. Published data exploring stereotactic or proton beam percutaneous irradiation have revealed,that hepatocellular carcinoma (HCC) is radiosensitive to certain protocols. In Phase I and II studies, the investigators investigated the potential role of local irradiation in primary and secondary liver tumors employing a Iridium192 source. The promising results of previous studies indicate that CT-guided brachytherapy might play a role in the treatment of unresectable HCC. Therefore, the investigators started a randomized, controlled, clinical Phase-II study to evaluate the efficacy and survival-benefits of brachytherapy versus transarterial chemoembolization in patients with unresectable HCC.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
77
catheter placed into the tumor by CT-guidance, radiation with iridium 192
application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
Clinic of Diagnostic Radiology and Nuclear Medicine, Medical Faculty, University Magdeburg
Magdeburg, Saxony-Anhalt, Germany
Time to untreatable progression
Time frame: the follow up period
Time to progression
Time frame: the follow up period
Overall survival
Time frame: the follow up period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.